

Opportunities For the Medical Sector in Thailand

Innovation and R&D Support For the Healthcare Sector In Thailand

Prof. Dr. Sansanee Chaiyaroj

Program Management Unit For Competitiveness (PMU-C)

Webinar Platform 10:00-11:50 am


July 1, 2021

Organization of Thai Research and Innovation Agencies










Research Budget Allocations from Thailand Science Research and Innovation (TSRI)










Medicine and healthcare **RDI funds** comes from 1. HSRI

PMUC Funding Schemes









- -Universities (Academia)
- -University-Industry JV
- -Spin-off Companies
- -Start-ups
- -SME in collaboration with University
- Multinational Company with university collaboration




Triple & Quadruple Helix Model of Innovation

Strategic Programs of PMUC










Different Research Areas of Medical Innovation









Medical Device Industry

Research, Development, Innovation and Manufacturing

Example I. Siam BioScience Co., Ltd.










Value Chain of Realtime RT-PCR Diagnostic Kit Development to Market



Open Innovation:

To Increase Confidence in Quality, Manufacturing, and Development of Second Generation Product and Shorten Time to Market











Production of Enzymes for Realtime RT-PCR: SBS-**BiotechRabbit GmbH** Other Realtime PCR Diagnostic kits **Production of Reagents for** to ASEAN, Europe, Latin America **Master Mix** Ideas **Analytical technologies** Other industry markets External technologies **SAR-CoV2** Realtime RT-PCR Diagnostic **Quality Assessment and Validation** Kits to ASEAN Countries. **Primers and Probes Design Department of Medical Science,**

Proof-of-Concept with Clinical Samples (Mahidol University Ramathibodi Hospital)

MOPH

Advanced Therapeutic Medicinal Products







Mahidol University

Thaifoods Group. Pcl

SCIPT
GENEPEUTIC BIO CO.,LTD.
USUTA IAIUWĀN JUJO ANNA

National Science and Technology
Development Agency


Mr. Somphote Ahunai CEO of Energy Absolute, P





The Thailand Board of Investment (BOI) has approved business promotions for new projects in the field of advanced biotechnology, worth a combined 2.4 billion baht (around USD78 million) in investment, which include Genepeutic Bio, a biotech startup for advance therapeutic medical products (ATMPs) manufacturing.

The Mahidol/TCELS CD19 CAR constructs resulted from the research works developed by Prof. Dr. Suradej Hongeng and his team, Ramathibodi hospital, Mahidol University. The phase I clinical trial for evaluating toxicity and efficacy is expected to begin in early 2022. The CD19 CAR T-cells using in the clinical trial will be manufactured in Genepeutic Bio production facility.



CAR T-Cell Immunotherapy TURNING THE BODY INTO A CANCER FIGHTER.

Botanical Extracts: Kratom and others













Interpharma





A holding company listed in Stock Exchange of Thailand and specialize in research & development, production and distribution of holistic healthcare products for both human and animal

55% Intervetta
60% Interpetrina

- A company specialize in research & development and distribution of animal healthcare products
- A joint venture company between Interpharma PCL and Asian Sea
 Corporation PCL, specialized in research and development of innovative pet food products

00%

MODERN

MODERN

DEW LINGSU WYSUN SING

MODERN PHARMA CO, LTD.

- A pharmaceutical company developing & producing pharmaceutical products for human and animals.
- นอีบัก อีนเตอร์ฟาร์มา-ซีอีตัา จำกัด * A joint venture company between Interpharma PCL and Thai Union Group PCL specialized in research and development of innovative fish based Nutraceuticals

8 1 9

CDMO: Siam BioScience Co.,Ltd. Kingen Biotech Co., Ltd. Bionet Asia Co., Ltd.

Growth Factors>>> Cosmeceuticals and Wound Healings Vaccine and Biologics Development and Productions

				harna Cost	eticeut	arch	
	Abbrev.	Name	Biog	s, Or	Rese	Function	Status
	EGF	Epidermal growth factor	*	*	*	1,4	Finish
	a/bFGF	acidic/basic fibroblast growth factor		*	*	2,3,4,5	Finish
	IGF-1/2	Insulin-liked growth factor 1/2	*	*	*	1,2	Finish
	VEGF	Vascular epithilial growth factor		*	*	5	Finish
	TGF-B1	Transforming growth factor		*	*	1,2,3	Finish
	KGF	Keratinocyte growth factor	*	*	*	1	Finish
	PDGF	Plelete-derived growth factor	*		*	2,3,4	Finish
	IL-2	Interleukin-2	*		*	Proliferation	Finish
	BMP-2	Bone morphogenesis protien-2			*	Proliferation	Finish
	SCF	Stem-cell growth factor	•		*	Proliferation	Not start
	NGF	Nerve growth factor	•		*	Proliferation	Not start








Strategic Programs of PMUC















BIOCOMPATIBILITY TESTING OF MEDICAL DEVICES

Irritation Tests ISO 10993-10

Cytotoxicity Tests ISO10993-5

Genotoxicity Tests ISO10993-3

Sensitization Tests ISO10993-10

Hemocompatibility Tests ISO 10993-4



Systemic Toxicity Testing ISO 10993-11

Implantation Tests ISO 10993-6

Ocular Biocompatibility
Test
ISO 9394

Cytotoxicity Test of Contact Lenses ISO 18189

Biocompatibility **Testing**

- Toxicological <u>testing</u> of devices comes under the rubric of "Biocompatibility Testing"
- Safety assessment of medical devices is guided by toxicology studies recommended by the Biological Evaluation of Medical Devices <u>Technical Committee of the International Organization for</u> <u>Standardization (ISO) documents 10993</u> (ISO 10993 Technical Committee).
 - The ISO guidelines are compendial methods;
 - described in the U.S. Pharmacopoeia (USP)




rior. Sansance Charyaro



CLINIXIR arose from a PPP among 8 medical faculties of 6 Thai global universities and BBL/Bualuang Venture.



UCLINIXIR



Clinixir
One-stop clinical research services
for Thailand


Clinixir Co. Ltd.

Different Research Areas of Medical Innovation









Medical Device Industry

Research, Development, Innovation and Manufacturing





In Summary

